| Ulcerative Colitis

Uceris vs Zeposia

Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.

Deep comparison between: Uceris vs Zeposia with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsZeposia has a higher rate of injection site reactions vs Uceris based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Zeposia but not Uceris, including UnitedHealthcare

Category

Uceris

Zeposia

At A Glance

RouteRectal foam

FrequencyTwice daily, then once daily

ClassGlucocorticosteroid

RouteOral

FrequencyOnce daily

ClassS1P receptor modulator

Indications

Ulcerative Colitis

Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis, Secondary Progressive
Clinically isolated syndrome
Ulcerative Colitis

Dosing

Ulcerative Colitis 1 metered dose administered rectally twice daily for 2 weeks, followed by 1 metered dose administered rectally once daily for 4 weeks.

Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome, Ulcerative Colitis Initiate with 7-day titration (0.23 mg once daily days 1-4, 0.46 mg once daily days 5-7); maintenance dose 0.92 mg orally once daily starting day 8; patients with mild or moderate hepatic impairment (Child-Pugh class A or B) take 0.92 mg once every other day after titration.

Contraindications

History of known hypersensitivity to budesonide or any ingredient of UCERIS rectal foam, including anaphylaxis

Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure in the last 6 months
Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
Severe untreated sleep apnea
Concurrent use of a monoamine oxidase (MAO) inhibitor

Drug Interactions

1059View drug interactions

1035View drug interactions

Adverse Reactions

Most common (>=2%) Decreased blood cortisol, adrenal insufficiency, nausea

Serious Hypercorticism and adrenal axis suppression, steroid withdrawal symptoms, increased susceptibility to infection, other glucocorticosteroid effects

Postmarketing Hypertension, pancreatitis, pyrexia, peripheral edema, anaphylactic reactions, dizziness, benign intracranial hypertension, mood swings, pruritus, maculopapular rash, allergic dermatitis

Most common (>=4%) Upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, hypertension (MS); liver test increased, upper respiratory infection, headache (UC)

Serious Infections, progressive multifocal leukoencephalopathy, bradyarrhythmia and AV conduction delays, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, cutaneous malignancies, posterior reversible encephalopathy syndrome

Postmarketing Liver injury

Pharmacology

Budesonide is a synthetic non-halogenated glucocorticosteroid that exerts local anti-inflammatory activity via glucocorticosteroid receptor binding; it undergoes extensive first-pass hepatic metabolism via CYP3A4, resulting in low systemic bioavailability.

Ozanimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in MS and ulcerative colitis is unknown but may involve reduced lymphocyte migration into the CNS and intestine.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Uceris